Yorkville Advisors Global’s Scinai Immunotherapeutics SCNI Stock Holding History

Yorkville Advisors Global’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,000	Closed	-$95.8K	–	37
2025 Q2	$95.8K	Buy	+42,000	New	+$106K	0.03%	18

Other funds holding SCNI

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Yorkville Advisors Global's SCNI Position: Q3 2025 in Review

Yorkville Advisors Global sold out of Scinai Immunotherapeutics (SCNI) in Q3 2025, closing a stake of 42,000 shares — an estimated $95.8K sold.

Yorkville Advisors Global first reported a position in SCNI in Q2 2025 and held it in 1 quarter. The position peaked at $95.8K in Q2 2025. 6 funds tracked by Wall St. Rank hold SCNI as of Q3 2025.

Yorkville Advisors Global reported no remaining Scinai Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
Yorkville Advisors Global sold 42,000 Scinai Immunotherapeutics shares in Q3 2025, an estimated $95.8K.
Yorkville Advisors Global first reported a position in Scinai Immunotherapeutics in Q2 2025 and held it in 1 quarter.
Yorkville Advisors Global's Scinai Immunotherapeutics position peaked at $95.8K in Q2 2025.
6 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2025.

Based on Yorkville Advisors Global's 13F filing for Q3 2025, filed 18 Nov 2025.